FDA refuses to file Pipex’s Coprexa
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pipex believes that FDA's transfer of the NDA for Coprexa (oral tetrathiomolybdate) from the initial review division that conducted pre-NDA meetings to a new review division is the reason that the agency refused to file the application for initially-presenting neurologic Wilson's disease. The NDA was transferred to the other division in late December because a medical group in that division had expertise in diseases resulting from inborn metabolic errors. "Pipex believes that the clinical and nonclinical deficiencies cited by the FDA were already discussed, resolved and agreed upon with FDA during … pre-NDA meetings," the firm said Jan. 29 (1Pharmaceutical Approvals Monthly October 2007, In Brief). Pipex maintains the citations are substantive review issues and should be considered during review of the NDA. Pipex and FDA are scheduled to meet by the end of February to discuss the RTF decision...
You may also be interested in...
Pipex expects November NDA filing for Coprexa
Ann Arbor-based Pipex Pharmaceuticals anticipates filing its lead compound, Coprexa (oral tetrathiomolybdate), in November for the treatment of initially-presenting neurologic Wilson's disease, the firm announces Sept. 21 after completing pre-NDA meetings with FDA. Pipex is also developing oral tetrathiomolybdate - an oral small-molecule, anti-copper agent - for fibrotic disorders...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.